Por: CNN Health November 15, 2022
CNN — An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday. Gantenerumab is part of a class of injected drugs that are designed to remove sticky protein pieces called beta amyloid from the brain. Beta amyloid buildup is a hallmark of Alzheimer’s disease. Most of these drugs have worked as intended to... + full article
ABC7 USA Health December 01, 2022
treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with certain serious adverse events.Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
Alzheimer's drug trial shown to slow cognitive decline in long fight against dementia | CNBC
CNBC USA Health November 30, 2022
Alzheimer's is the most common form of dementia, a general term for loss of memory, language, and other thinking abilitiesBrian B. Bettencourt Toronto Star Getty ImagesA trial of an experimental Alzheimer's drug has been hailed as a new era in the beleaguered fight to... + más
Experimental drug appears to slow progression of Alzheimer's disease but raises safety concerns | ABC7
Forbes USA Tech November 15, 2022
Doctor viewing brain scans for possible disease or damage.getty In results posted today, Roche’s investigational Alzheimer’s Disease biologic, gantenerumab, to a statistically significant degree compared to placebo. The measured were remembering, solving problems,... + más
Alzheimer's Q&A: FDA could fast-track new drug, but positive effects debatable | The Advocate
Forbes USA Tech October 22, 2022
A person walks on a suspended rope bridge in the clouds. Extreme attraction.getty This article is the fourth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in , , and of the series. The pharmaceutical and biotech companies, Eisai and... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
Variety of factors play a role in the development of Alzheimer's | The Advocate
The Advocate USA Health September 26, 2022
Why do people resist enrolling in clinical trials for Alzheimer’s disease?Some of the key challenges that researchers face in conducting studies on Alzheimer’s disease and recruiting candidates include barriers such as lack of time, lack of available diagnostic clinical... + más
Alzheimer's Treatment Shows Promise in Early Results of Study, Drugmaker Says | NBC 6 South Florida
Facebook ad ban may squelch medical research recruitment | Politico
Newsweek USA Health September 24, 2022
The Alzheimer's Association defines Alzheimer's as a brain disease that causes a slow decline in memory, thinking and reasoning skills. Dementia refers to the symptoms of Alzheimer's that can worsen over time.They predict that by 2050, the number of people aged 65... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
How To Spot The Early Signs Of Alzheimer's | Newsweek
About iurex | Privacy Policy | Disclaimer |